Roche’s Actemra (tocilizumab) Receives Approval to Combat Coronavirus Complications in China

Shots:

• China’s National Health Commission reports in its treatment guidelines that Roche’s Actemra can be used to treat coronavirus patients with serious lung damage and high IL-6 levels
• Researchers are assessing Actemra in clinical studies & is expected to include 188 coronavirus patients and running until May 10, 2020, with the goal to evaluate efficacy and safety of the drug in coronavirus patients with CRS
• Actemra is a biologic therapy and has received the US FDA’s approval in 2010 for RA, act by inhibiting high IL-6 protein levels

Click here ­to­ read full press release/ article | Ref: Nasdaq | Image: Pinterest